组蛋白甲基转移酶EZH2在宫颈癌中的研究进展

doi:10.12280/gjfckx.20210940

摘要/Abstract

摘要：

果蝇zeste基因增强子同源物2（enhancer of zeste homolog 2,EZH2）是一种组蛋白赖氨酸甲基转移酶（histone lysine methyltransferase,HKMT）。EZH2主要通过调控组蛋白H3第27位赖氨酸（H3K27）甲基化修饰参与肿瘤的发生、发展等一系列恶性生物学行为,在表观遗传修饰过程中发挥重要作用。研究显示EZH2在宫颈癌中过表达,并且与患者的不良预后密切相关。EZH2可以促进宫颈癌的增殖、迁移、侵袭、血管生成、耐药以及免疫逃逸等行为。对EZH2的深入研究有望为宫颈癌提供新的分子靶点,从而有助于宫颈癌的早期诊断、预后评估和靶向治疗。

关键词: Zeste同源蛋白2增强子, 宫颈肿瘤, 甲基化, 细胞增殖, 细胞凋亡

Abstract:

Enhancer of zeste homolog 2 (EZH2) is a kind of histone lysine methyltransferase (HKMT). It participates in the malignant behavior of tumorigenesis and development mainly through regulating the methylation modification of H3K27, which plays an important role in epigenetic modification. The researches show that EZH2 is highly expressed in cervical cancer and it is closely related to the poor prognosis of patients. EZH2 takes part in the proliferation, migration, invasion, angiogenesis, drug resistance and immune escape of cervical cancer. The in-depth study of EZH2 is expected to provide a new therapeutic target for cervical cancer, so as to contribute to the early diagnosis, prognosis evaluation and targeted treatment of cervical cancer.

Key words: Enhancer of zeste homolog 2 protein, Uterine cervical neoplasms, Methylation, Cell proliferation, Apoptosis

王昭娣, 王悦. 组蛋白甲基转移酶EZH2在宫颈癌中的研究进展[J]. 国际妇产科学杂志, 2022, 49(3): 291-295.

WANG Zhao-di, WANG Yue. Research Progress of Histone Methyltransferase EZH2 in Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(3): 291-295.

参考文献 36

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Harvey ZH, Chen Y, Jarosz DF. Protein-Based Inheritance: Epigenetics beyond the Chromosome[J]. Mol Cell, 2018, 69(2):195-202. doi: 10.1016/j.molcel.2017.10.030. doi: 10.1016/j.molcel.2017.10.030
[3]	Jones BA, Varambally S, Arend RC. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer[J]. Mol Cancer Ther, 2018, 17(3):591-602. doi: 10.1158/1535-7163.MCT-17-0437. doi: 10.1158/1535-7163.MCT-17-0437
[4]	冷雪媛, 范恒. EZH2在消化系统肿瘤中的研究进展[J]. 世界华人消化杂志, 2021, 29(5):242-247. doi: 10.11569/wcjd.v29.i5.242. doi: 10.11569/wcjd.v29.i5.242
[5]	Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders[J]. Eur J Hum Genet, 2000, 8(3):174-180. doi: 10.1038/sj.ejhg.5200439. doi: 10.1038/sj.ejhg.5200439 pmid: 10780782
[6]	Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins[J]. Annu Rev Genet, 2004, 38:413-443. doi: 10.1146/annurev.genet.38.072902.091907. doi: 10.1146/annurev.genet.38.072902.091907 pmid: 15568982
[7]	Labbé DP, Sweeney CJ, Brown M, et al. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup[J]. Clin Cancer Res, 2017, 23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. doi: 10.1158/1078-0432.CCR-17-0413
[8]	Azizmohammadi S, Azizmohammadi S, Safari A, et al. High-Level Expression of RIPK4 and EZH2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer[J]. Oncol Res, 2017, 25(4):495-501. doi: 10.3727/096504016X14749735594687. doi: 10.3727/096504016X14749735594687 pmid: 27697098
[9]	Makk E, Bálint L, Cifra J, et al. Robust expression of EZH2 in endocervical neoplastic lesions[J]. Virchows Arch, 2019, 475(1):95-104. doi: 10.1007/s00428-019-02550-8. doi: 10.1007/s00428-019-02550-8
[10]	唐梅, 尤共平, 林丽慧, 等. EZH2和Ki-67在宫颈癌组织中的表达及其临床意义[J]. 中国妇产科临床杂志, 2018, 19(1):12-15. doi: 10.13390/j.issn.1672-1861.2018.01.005. doi: 10.13390/j.issn.1672-1861.2018.01.005
[11]	Jin M, Yang Z, Ye W, et al. Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma[J]. Oncol Lett, 2015, 10(2):857-862. doi: 10.3892/ol.2015.3319. doi: 10.3892/ol.2015.3319
[12]	Liu Y, Liu T, Bao X, et al. Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis[J]. Int J Gynecol Pathol, 2014, 33(3):218-224. doi: 10.1097/PGP.0b013e31829c6574. doi: 10.1097/PGP.0b013e31829c6574
[13]	卢春冬, 蔡惠芬, 王文婷. 宫颈癌组织中蛋白EZH2的异常表达及其临床意义研究[J]. 中华保健医学杂志, 2020, 22(3):172-175. doi: 10.3969/j.issn.1674-3245.2020.03.020. doi: 10.3969/j.issn.1674-3245.2020.03.020
[14]	Chen Q, Zheng PS, Yang WT. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma[J]. Oncotarget, 2016, 7(24):36115-36129. doi: 10.18632/oncotarget.8741. doi: 10.18632/oncotarget.8741
[15]	冀静, 李琛, 黄慧芳, 等. 沉默EZH2基因表达对宫颈癌细胞增殖能力影响的分析[J]. 基因组学与应用生物学, 2017, 36(7):2586-2592. doi: 10.13417/j.gab.036.002586. doi: 10.13417/j.gab.036.002586
[16]	Ding M, Zhang H, Li Z, et al. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer[J]. Clin Exp Pharmacol Physiol, 2015, 42(5):458-464. doi: 10.1111/1440-1681.12382. doi: 10.1111/1440-1681. 12382
[17]	冀静, 黄康榕, 黄慧芳, 等. siRNA沉默EZH2基因对人宫颈癌细胞侵袭转移的影响[J]. 西安交通大学学报(医学版), 2017, 38(5):684-687. doi: 10.7652/jdyxb201705012. doi: 10.7652/jdyxb201705012
[18]	Zhang H, Yan T, Liu Z, et al. MicroRNA-137 is negatively associated with clinical outcome and regulates tumor development through EZH2 in cervical cancer[J]. J Cell Biochem, 2018, 119(1):938-947. doi: 10.1002/jcb.26259. doi: 10.1002/jcb.26259
[19]	Yang Y, Liu Y, Li G, et al. microRNA-214 suppresses the growth of cervical cancer cells by targeting EZH2[J]. Oncol Lett, 2018, 16(5):5679-5686. doi: 10.3892/ol.2018.9363. doi: 10.3892/ol.2018.9363
[20]	Song H, Liu Y, Jin X, et al. Long non-coding RNA LINC01535 promotes cervical cancer progression via targeting the miR-214/EZH2 feedback loop[J]. J Cell Mol Med, 2019, 23(9):6098-6111. doi: 10.1111/jcmm.14476. doi: 10.1111/jcmm.14476
[21]	Min H, He W. Long non-coding RNA ARAP1-AS1 promotes the proliferation and migration in cervical cancer through epigenetic regulation of DUSP5[J]. Cancer Biol Ther, 2020, 21(10):907-914. doi: 10.1080/15384047.2020.1806641. doi: 10.1080/15384047.2020.1806641
[22]	Zhang S, Zhang G, Liu J. Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b[J]. APMIS, 2016, 124(8):649-658. doi: 10.1111/apm.12555. doi: 10.1111/apm.12555
[23]	Chi C, Li M, Hou W, et al. Long Noncoding RNA SNHG7 Activates Wnt/β-Catenin Signaling Pathway in Cervical Cancer Cells by Epigenetically Silencing DKK1[J]. Cancer Biother Radiopharm, 2020, 35(5):329-337. doi: 10.1089/cbr.2019.3004. doi: 10.1089/cbr.2019.3004
[24]	Wang XH, Li J. CircAGFG1 aggravates the progression of cervical cancer by downregulating p53[J]. Eur Rev Med Pharmacol Sci, 2020, 24(4):1704-1711. doi: 10.26355/eurrev_202002_20345. doi: 10.26355/eurrev_202002_20345
[25]	Wang Q, Zhuo Z, Yu H, et al. Circ_0019435 Exerts Its Functions in the Cellular Process of Cervical Cancer via Epigenetically Silencing DKK1 and PTEN[J]. Reprod Sci, 2021, 28(10):2989-2999. doi: 10.1007/s43032-021-00625-z. doi: 10.1007/s43032-021-00625-z
[26]	Fathy A, Abdelrahman AE. EZH2, Endothelin-1, and CD34 as Biomarkers of Aggressive Cervical Squamous Cell Carcinoma: An Immunohistochemical Study[J]. Turk Patoloji Derg, 2018, 34(2):150-157. doi: 10.5146/tjpath.2018.01425. doi: 10.5146/tjpath.2018.01425
[27]	马雪梅, 魏璇, 郭兴巧, 等. EZH2与VEGF-C在宫颈上皮内瘤变及宫颈癌组织中的表达及意义[J]. 中国煤炭工业医学杂志, 2017, 20(7):846-849. doi: 10.11723/mtgyyx1007-9564201707023. doi: 10.11723/mtgyyx1007-9564201707023
[28]	段继惠, 杨磊, 穆红, 等. 抑制EZH2表达对宫颈癌细胞凋亡的影响及机制[J]. 山东医药, 2019, 59(11):1-4. doi: 10.3969/j.issn.1002-266X.2019.11.001. doi: 10.3969/j.issn.1002-266X.2019.11.001
[29]	Qu X, Li Y, Wang L, et al. LncRNA SNHG8 accelerates proliferation and inhibits apoptosis in HPV-induced cervical cancer through recruiting EZH2 to epigenetically silence RECK expression[J]. J Cell Biochem, 2020, 121(10):4120-4129. doi: 10.1002/jcb.29646. doi: 10.1002/jcb.29646
[30]	Cai L, Wang Z, Liu D. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression[J]. Tumour Biol, 2016, 37(5):6359-6369. doi: 10.1007/s13277-015-4416-9. doi: 10.1007/s13277-015-4416-9
[31]	张婷婷, 彭慧霞. microRNA217逆转人宫颈癌细胞顺铂耐药及其作用机制[J]. 陕西医学杂志, 2017, 46(10):1348-1350. doi: 10.3969/j.issn.1000-7377.2017.10.010. doi: 10.3969/j.issn.1000-7377.2017.10.010
[32]	Wang Y, Zhao E, Zhang Z, et al. Association between Tim-3 and Gal-9 expression and gastric cancer prognosis[J]. Oncol Rep, 2018, 40(4):2115-2126. doi: 10.3892/or.2018.6627. doi: 10.3892/or.2018.6627
[33]	Zhang L, Tian S, Pei M, et al. Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim-3 and galectin-9, in cervical cancer[J]. Oncol Rep, 2019, 42(6):2655-2669. doi: 10.3892/or.2019.7388. doi: 10.3892/or.2019.7388 pmid: 31661141
[34]	Holland D, Hoppe-Seyler K, Schuller B, et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein[J]. Cancer Res, 2008, 68(23):9964-9972. doi: 10.1158/0008-5472.CAN-08-1134. doi: 10.1158/0008-5472.CAN-08-1134
[35]	唐雨琪, 李凡, 陈万涛. 抗癌靶点EZH2及其抑制剂的研究进展[J]. 中南药学, 2021, 19(7):1398-1404. doi: 10.7539/j.issn.1672-2981.2021.07.024. doi: 10.7539/j.issn.1672-2981.2021.07.024
[36]	丁沐阳, 蒋文军, 张力, 等. EZH2抑制剂对宫颈癌HeLa细胞的抑制作用[J]. 西安交通大学学报(医学版), 2015, 36(5):633-636,681. doi: 10.7652/jdyxb201505012. doi: 10.7652/jdyxb201505012